FANCC and breast cancer: Given the involvement of the FA complex in the HR process, some clinical trials are evaluating the efficacy of PARP inhibitors in patients with metastatic BC and germline alterations of PALB2, BRIP1, and other FA genes such as FANCA, FANCC, FANCD2, FANCE, FANCF, and FANCM [136].